Institutional accumulation regime. Strong business quality combined with supportive market trend. Valuations remain demanding and supported by current metrics.
SENTINEL REVIEW
Abbott India Ltd. (ABBOTINDIA)•Updated yesterday
🛡️ Sound Structural Profile: In QNone FYNone, Abbott India Ltd. maintains a stable financial profile with no reported revenue or profit, reflecting a nominal operational baseline. The company’s composite risk score of 0.0/100 and sector percentile of 50.0th indicate a balanced structural position, with governance as the primary driver of its risk profile. Balance sheet integrity is preserved, with no active forensic signals triggered and a nominal debt base of ₹0.0 Cr. The absence of operating cash flow data and trade receivables further confirms liquidity stability, though further analysis is required to assess long-term financial health. The company’s structural resilience aligns with Flagium’s stable surveillance range, pending updates to its financial trajectory.
- ✓Risk score improved (QoQ change: 0 pts)
- ✓Profitability margins pressure eased
- ✗Growth expectations are demanding
- ✗Market structure is declining (Stage 4)
- ✓Institutional flow regime is Accumulation (0.53σ)
- ✗Share price is down -3.1% this quarter (from ₹27,125 on 30 Sept to ₹26,275)
- 🟢No severe forensic red flags active for ABBOTINDIA
- 🟠Track earnings quality and working capital trends in next filing
- 🟢Maintain routine quarterly surveillance; no governance escalation required
- 0 ptsClean Profile (Zero Penalties)
Divergence Radar
Structural Matrix
Risk vs Price TimelineVisualizing the historical relationship between the structural risk score and stock price movement over time.
| Duration | Perf. | Sector Avg | Divergence |
|---|---|---|---|
| 1 Week | +2.32% | -1.46% | +3.78% |
| 1 Month | -1.74% | -6.69% | +4.95% |
| 6 Months | +3.3% | +6.82% | -3.52% |
| 1 Year | -11.74% | +8.93% | -20.67% |
| 2 Year | -6.3% | +47.64% | -53.95% |
| 3 Year | +19.21% | +125.5% | -106.29% |
Business Analysis Methodology
Business analysis focuses on structural risk inside the company. Flagium monitors earnings quality, balance sheet strength, liquidity, governance, competitive position, and growth sustainability to identify areas where risk may be increasing or decreasing before it becomes obvious in reported results.
Financial profile remains stable for now. Pressure has stabilized in balance sheet stress. This indicates that forensic pressure is currently receding. No major change in risk trend.
Risk Score Composition
Investment Risk Thesis
Current risk score has remained stable (0 → 0) over 12 quarters.
- Operating cash flow sustainability
- Working capital discipline
Risk Drivers (Active Warnings)
No active warnings detected.
Primary Driver & Insights
Forensic risk profile is stable. No severe operating or financial anomalies are currently pressure-testing business resilience.
Active Risk Objects (8)Free Preview (2 of 8)
Inventory growth (1.0%) significantly outpaced revenue growth (-2.7%).
Inventory overhang is clearing. Stock levels are normalizing as sales momentum returns.
ABBOTINDIA: Trade Receivables growth outpaced Revenue by +114.9 pp (DSRI: 5.53x).
Collection efficiency is improving. Debtor days are trending back toward normal levels.
Unlock All 8 Forensic Signals (6 Additional Warnings Gated)
Free accounts preview the top 2 highest-impact warning signals. Upgrade to Flagium Pro to inspect all 8 active forensic detectors, multi-quarter duration streaks, and financial stress metrics for Abbott India Ltd..
Statutory Note: Forensic signals are algorithmic quantitative observations derived from publicly filed XBRL disclosures and do not constitute allegations of legal misconduct or investment recommendations.
Unlock Interactive Signal Evidence Dossier
Access complete multi-quarter financial evidence, 5-KPI snapshot strips, diagnostic hypotheses, and 1-page forensic PDF dossiers for Abbott India Ltd..
Structural Risk Attribution
Deterministic quarter-on-quarter causal decomposition grounded in statutory exchange filings.
Structural History · Last 12 QuartersHistorical Trajectory (12Q)
Risk profile remained stable this quarter, with no new forensic alarms or critical threshold escalations detected.
Business Resilience & Benchmark Context
Overall: STRONGPEER COMPARISON MATRIX
Ranked surveillance & credit risk comparison against sector peers
Stable
Stable
Stable
Stable
Watch
Watch
* Peer comparison is based on risk signals, not valuation or returns.
Unlock 5-Year Forensic Divergence Cockpit
Access multi-year visual divergence charts (EBITDA vs CFO Cash Gap, Receivables Decoupling Spread, and Debt vs FCF Burn) for Abbott India Ltd..
FINANCIAL STATEMENTS
Working Capital & Forensic Monitor
Operating Cycle Disclosures·4 Fiscal Years
Working Capital Schedule (INR Cr)
| Metric / Ratio | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
Trade Receivables(₹ Cr) | 362 | 380 | 319 | 319 |
Inventories(₹ Cr) | 947 | 882 | 620 | 649 |
Trade Payables(₹ Cr) | 1,107 | 1,058 | 1,003 | 892 |
Net Working Capital(₹ Cr) | 202 | 204 | -64 | 76 |
Working Capital / Sales(%) | 2.9% | 3.2% | -1.1% | 1.4% |
Cash Conversion & Operating Cycle (Days)
| Metric / Ratio | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
Cash Conversion Cycle (CCC)(days) | 11d | 12d | -4d | 5d |
Debtor Days (DSO)(days) | 19d | 22d | 20d | 22d |
Inventory Days (DIO)(days) | 50d | 50d | 39d | 44d |
Creditor Days (DPO)(days) | 58d | 60d | 63d | 61d |
Forensic Accounting Monitor & Divergences
| Metric / Ratio | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
Receivable Growth vs Sales (Δ)(%) | -13.0% | +9.6% | -9.3% | — |
Inventory Growth vs Sales (Δ)(%) | -0.7% | +32.8% | -13.9% | — |
Asset Growth vs Sales (Δ)(%) | +1.8% | +4.4% | +4.6% | — |
Earnings-to-Cash Divergence (PAT - CFO)(₹ Cr) | 233 | 403 | -12 | 56 |
Accrual Ratio (Accruals / Avg Assets)(%) | 3.8% | 7.3% | -0.2% | 1.2% |
Operating Cash Realisation (CFO / EBITDA)(%) | 72.3% | 61.5% | 86.3% | 77.9% |
Capitalisation Intensity (CWIP / Assets)(%) | 1.7% | 5.7% | 4.3% | 1.9% |
Industry Intelligence
Pharmaceutical Sector KPIs| Operating Driver | Quarter | Current Value | Change (QoQ) | Change (YoY) | Industry Median |
|---|---|---|---|---|---|
| Q1 FY2027 | 48.6% | +150 bps ↑ Operating efficiency gains | +280 bps ↑ Operating efficiency gains | 64.0% |
Understanding Pharmaceutical KPIs
Concall & Management Takeaways
No investor earnings call transcripts transcribed for this scrip.
Earnings call intelligence is automatically populated when companies conduct quarterly earnings calls with institutional investors and publish transcripts.
Business quality remains strong.
Current forensic pressure is elevated and improving.
Key risks remain concentrated in growth sustainability and operating leverage.
The structural architecture is currently robust. Capital resilience buffers in balance sheet stress remain well-maintained against forensic benchmarks. Systematic scans of core structural metrics confirm the absence of material structural stress. The current structural trajectory supports a stable risk outlook.
Market Expectation Engine
Investor Translation • What the market price is expecting
Expectation EngineAt the current price of ₹26,275, the market expects this company to grow its net profits by 18.0% every year for the next 5 years. If you think the company will grow faster than 18.0%, current market prices reflect a discount relative to that growth assumption.
Sentinel Takeaway:The market expects future growth significantly above the company's historical delivery. Current market expectations appear demanding relative to the business's track record, resulting in higher expectation risk.
Using the Discounted Cash Flow (DCF) model, the market is pricing ABBOTINDIA for 18.0% long-term growth versus 12.3% historical delivery. Current expectations appear demanding, and historical fundamentals provide strong support.
Business Delivery Capacity
Performance quality vs historical benchmarksHistorical business performance currently provides robust support for the market's implied growth assumptions. Improvement in revenue growth and operating efficiency would strengthen expectation support.
WHY IS EXPECTATION RISK ELEVATED?
Valuation Context
WHAT MUST HAPPEN FOR CURRENT PRICE TO BE CORRECT?
| Assumption Metric | Required (To justify current price) | Historical Delivery (Average) | Fulfillment Assessment |
|---|---|---|---|
| Revenue Growth (CAGR) | 18.0% | 12.3% | Demanding |
| Operating Margin (EBIT) | 27.0% | 25.4% | Demanding |
| Free Cash Flow Conversion | 67.5% | 70.4% | Achievable |
*Required metrics indicate the operating efficiency and revenue expansion parameters that must be sustained long-term to justify the current stock price.
The current valuation assumes business performance well above the company's historical record. Historical operating performance currently provides partial evidence that these expectations are sustainable. Continued stronger profitability would be required to justify current pricing.
Market Structure Methodology
Flagium separates Business Risk from Market Structure. Business analysis explains what is happening inside the company. Market Structure measures how investors are behaving through price trends, momentum, participation, and institutional activity. Divergences between the two often reveal important transitions before they become obvious.
The stock remains in a confirmed Stage 4 declining phase. Although institutional participation has improved, trend quality remains weak and momentum continues to deteriorate. Current price action does not yet confirm a structural recovery.
What Is Driving Market Structure?
Price structure remains weak despite stable underlying financial risk.
Market Cycle Stage Analysis
Stan Weinstein 4-Stage CycleMomentum & Institutional Flow
Methodology & Regulatory Disclaimer
Flagium AI is an automated financial data analytics and research platform providing quantitative risk, forensic, and valuation analytics for informational and educational purposes only. Flagium AI is not registered with SEBI as a Research Analyst or Investment Adviser under SEBI regulations. These analytics do not constitute financial planning, investment advice, or recommendations to buy, sell, or hold any security.
Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered Investment Adviser before acting on any data presented.
📬 Flagium Risk Brief — Track forensic risks on ABBOTINDIA & 3 market anomalies weekly
See a sample issue →